Evidence map›Paper›PMID 30808443›Full record

ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2019

Implementation and evaluation of the human papillomavirus (HPV) vaccination pilot for men who have sex with men (MSM), England, April 2016 to March 2017.

Michael Edelstein, Nalini Iyanger, Nicola Hennessy, David Mesher, Marta Checchi, Kate Soldan, Mark McCall, Julie Nugent, Jonathan Crofts, Janice Lo and 4 more

Abstract read
In one paragraph

Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Low vaccination coverage for human papillomavirus disease among young men who have sex with men, France, 2019.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2021
    Article
  14. HPV vaccine for men: Where to? (Review).Experimental and therapeutic medicine · 2021
    Review
  15. Assessment of the Potential of Vaccination to Combat Antibiotic Resistance in Gonorrhea: A Modeling Analysis to Determine Preferred Product Characteristics.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Michael EdelsteinImmunisation and countermeasures division, National Infection Service, Public Health England, London, United Kingdom.
Nalini IyangerImmunisation and countermeasures division, National Infection Service, Public Health England, London, United Kingdom.
Nicola HennessyImmunisation and countermeasures division, National Infection Service, Public Health England, London, United Kingdom.
David MesherBlood Safety, Hepatitis, Sexually Transmitted Infections (STI) and HIV service, National Infection Service, Public Health England, London, United Kingdom.
Marta ChecchiBlood Safety, Hepatitis, Sexually Transmitted Infections (STI) and HIV service, National Infection Service, Public Health England, London, United Kingdom.
Kate SoldanBlood Safety, Hepatitis, Sexually Transmitted Infections (STI) and HIV service, National Infection Service, Public Health England, London, United Kingdom.
Mark McCallBlood Safety, Hepatitis, Sexually Transmitted Infections (STI) and HIV service, National Infection Service, Public Health England, London, United Kingdom.
Julie NugentImmunisation and countermeasures division, National Infection Service, Public Health England, London, United Kingdom.
Jonathan CroftsImmunisation and countermeasures division, National Infection Service, Public Health England, London, United Kingdom.
Janice LoImmunisation and countermeasures division, National Infection Service, Public Health England, London, United Kingdom.
Richard GilsonMortimer Market Sexual Health Clinic, London, United Kingdom.
Karen PowellImmunisation and countermeasures division, National Infection Service, Public Health England, London, United Kingdom.
Mary RamsayImmunisation and countermeasures division, National Infection Service, Public Health England, London, United Kingdom.
Joanne YarwoodImmunisation and countermeasures division, National Infection Service, Public Health England, London, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOpportunistic human papillomavirus (HPV) vaccination for men who have sex with men (MSM) was piloted in sexual health clinics (SHC) in England between 2016 and 2018.

aimto evaluate the pilot's first year (April 2016-March 2017) in terms of feasibility, acceptability, uptake, impact and equity and interpret the outcome in the context of wide HPV vaccination policy.

methodsAttendance and uptake data from routine SHC surveillance datasets and a cross-sectional survey administered to individuals receiving the vaccine were analysed.

resultsAmong 18,875 eligible MSM, 8,580 (45.5%) were recorded as having received one HPV vaccine dose, decreasing slightly with increasing age, and uptake was higher in rural than urban areas. Survey results suggested that of those receiving the first dose of HPV vaccine, 8% were new attendees and that among those, less than 11% attended just to receive the vaccine. Of those having their first HPV vaccination, 95% indicated they would like to receive the next vaccine doses at the same clinic and 85% of patients reported accessing other services when visiting SHC for the first dose of vaccine.

conclusionAn opportunistic HPV vaccination programme for MSM can be delivered in an acceptable and, as far as can be evaluated, equitable manner, without major disruption to SHC and HIV clinics.

Indexed as

Health Knowledge, Attitudes, PracticeAdolescentAdultAge DistributionAmbulatory Care FacilitiesCross-Sectional StudiesFeasibility StudiesHomosexuality, MaleHumansImmunizationMalePapillomaviridaePapillomavirus InfectionsPapillomavirus VaccinesPatient Acceptance of Health CareProgram EvaluationPapillomavirus VaccinesEnglandHPVhuman papillomavirusimmunisationmen who have sex with menMSMpolicysexual healthsexually transmitted infectionsvaccinationvaccine

Identifiers

PMID30808443
PMCPMC6446955

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.